&w=3840&q=100)
Biocon share price pops 2% on CDSCO nod for diabetes drug; key details here
Biocon share price: Bengaluru-based biopharmaceutical company Biocon shares were in demand in a weak market on Tuesday, June 3, 2025, with the stock rising up to 1.85 per cent to hit an intraday high of 340.25 per share.
However, at 11:00 AM, Biocon share price was trading 0.49 per cent higher at 335.70 per share.
What is the reason behind the uptick in Biocon share price?
Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug. The company received approval from the Central Drugs Standard Control Organisation (CDSCO) for its Liraglutide drug substance, while its wholly owned subsidiary, Biocon Pharma, secured approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge).
Liraglutide is a synthetic analog of the GLP-1 peptide and is administered as a once-daily injection.
It is a generic version of Victoza and is indicated for the treatment of Type 2 Diabetes Mellitus in adults, adolescents, and children aged 10 years and older, as an adjunct to diet and exercise.
The original formulation was approved in the EU in 2009 and in the US in 2010.
The approvals were granted under the CDSCO's recently introduced 101 route, which recognises approvals from established global regulatory authorities, streamlining the approval process in India.
Siddharth Mittal, chief executive officer and managing director, Biocon, said: 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest numbers of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India''
'With GLP-1 therapies projected to be a substantive future growth driver for Biocon, the Company remains committed to reinforcing its position as a key player in this area,' Biocon said, in a statement.
Biocon Q4 results
Biocon reported a strong financial performance for the fourth quarter of FY25, with consolidated net profit surging 153 per cent year-on-year (Y-o-Y) to ₹344 crore, up from ₹136 crore in the same quarter last year.
Profit before tax (PBT) rose 53 per cent Y-o-Y to ₹487 crore. The company's Board also approved plans to raise up to ₹4,500 crore through various funding options, including qualified institutional placement (QIP), rights issue, or other permissible methods.
The robust growth was driven by solid performance across its generics, biologics, and research services segments.
Total consolidated revenue for the quarter stood at ₹4,454 crore, compared to ₹3,966 crore in Q4 FY24. Ebitda rose 16 per cent to ₹1,115 crore, with the margin maintained at 25 per cent. READ MORE
About Biocon
Biocon is a global biopharmaceutical company focused on developing and supplying affordable therapies for chronic diseases such as diabetes, cancer, and autoimmune disorders.
The company manufactures and markets novel biologics, biosimilars, complex small molecule APIs, and generic formulations across India, the US, Europe, and other key markets. It is also advancing a pipeline of novel immunotherapy assets.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
31 minutes ago
- Time of India
Surge in demand of Lord Ram idols in Prayagraj, Ayodhya & Kashi
1 2 Prayagraj: With the second phase of the consecration ceremony at the Lord Ram temple in Ayodhya , the demand for both small and large idols of Lord Ram made of fibre resin material has surged in Ayodhya, Varanasi and Prayagraj. The Sangam city and Lucknow-based handicraft units, which makes idols of Lord Ram, has received bulk orders for both sizes of idols, with heights of 6.5 ft and 1 ft, respectively. Anurag Asthana, who introduced the concept of shaping Lord Ram idols using clay modelling techniques and fibre resin materials, told TOI: "There is a record demand for the Lord Ram idols across the markets of the state. A team of five to six artisans is working round-the-clock to cope with the demand." He said the demand for particularly small idols has increased in view of the second phase of the consecration ceremony. Asthana, meanwhile, claimed that the artists first apply clay modelling to prepare the base and then use fibre resin materials to complete the idol. While it takes two to three days to prepare a small idol, it takes about 30 days for a big one. He said the demand for big idols was recorded more in the Prayagraj district. Interestingly, over 5,000 small idols of Lord Ram made of fibre resin material have already been sold out, and shoppers are more interested in purchasing the small idols due to their size and availability. Similarly, idols with a height of 6.5 feet are being made on demand only. Tourists flocking to the holy cities of UP from the rest of the country are purchasing these idols them for themselves as well as for gift purposes. Makers said that they have to take up double production of idols in both Prayagraj and Lucknow after witnessing the increasing demand in the markets.
Time of India
31 minutes ago
- Time of India
HSBC's next move could shake up India's venture debt play
HSBC's next move could shake up India's venture debt play Getty Images Synopsis London-based banking major has serious plans to start a venture debt fund in the country. India could well be HSBC's next destination after the UK, the US, Israel and Hong Kong to launch its Innovation Banking, a separate division for startups. By MANU P TOMS 5 Mins Read, Jun 05, 2025, 05:00 AM IST SHARE THIS NEWS Close Font Size Abc Small Small Abc Normal Normal Abc Large Close The 1GBP acquisition of the UK unit of collapsed Silicon Valley Bank in early 2023 opened new avenues for global banking major Hong Kong and Shanghai Banking Corp (HSBC). The move offered a quick start to its startup banking division, HSBC Innovation Banking. SVB's clients – 3,000 European startups and venture capital funds – became its customers overnight. HSBC Innovation Banking then spread its wings to the US, Israel, and Hong Kong. Its next
Hindustan Times
40 minutes ago
- Hindustan Times
Critically endangered vultures rewilded after landmark rehab effort in Maha
In a step towards conservation, three White-Rumped Vultures – classified as critically endangered on the International Union for Conservation of Nature (IUCN) Red List — have been successfully reintroduced into the wild after over three years in captivity. The release - carried out on May 22 in Sawarna, Nashik – is the result of a joint initiative between the Maharashtra forest department and Pune-based RESQ Charitable Trust. The three vultures were among four that had been transferred in October 2024 from Mumbai to the Wildlife Transit Treatment Centre (TTC), Pune, which specialises in recovery and release of injured or captive wildlife. When the birds first arrived in Pune, they were in a critical condition — suffering from severe nutritional deficiencies, deteriorated plumage, and a lack of basic survival instincts. One bird, later diagnosed as immunocompromised, succumbed to a chronic infection despite intensive care. The remaining three underwent a rigorous, science-led rehabilitation process. 'We focused on every element that affects survival in the wild—from restoring muscle strength and flight to reconditioning ground feeding behaviours,' said Dr Sushrut Shirbhate, senior veterinarian at RESQ CT. Over a period of seven months, the vultures showed remarkable improvement, transitioning from reluctant feeders to strong, self-reliant scavengers. Their progress was monitored through regular radiographs, blood tests, and morphometric evaluations. Behavioural conditioning was equally prioritised in that they were trained for sustained flight, thermoregulation, perching and social feeding with minimal human contact inside a dedicated aviary. Ahead of the release, all three vultures were ringed for identification. The largest among them was also fitted with a solar-powered GPS tracker to enable long-term post-release monitoring. Early tracking reports show that these birds have integrated into a wild flock and are exhibiting normal behaviour. Mahadev Mohite, deputy conservator of forests, Pune division, said, 'These birds weren't just from the same species—they were siblings. Releasing them into an existing wild population not only avoids inbreeding but helps rebuild natural social structures essential for the species' survival.' Initial tracking following release was conducted jointly by the Nashik forest department and RESQ CT's field team. It showed that the vultures have adapted well to their new environment. Monitoring will continue over the coming weeks to ensure long-term success. Once a common sight across India, White-Rumped Vultures have suffered a catastrophic population collapse of over 99% in recent decades, largely due to poisoning from the veterinary drug diclofenac, as well as habitat loss and food scarcity. Maharashtra is among the few states that still hosts remnant populations, particularly in ecologically rich zones like Nashik. Neha Panchamiya, founder and president of RESQ CT, said, 'Rehabilitating and releasing vultures is not only ethical—it is strategic. These birds perform an essential ecological function as scavengers. Their return reduces the burden on rescue centres, restores balance to ecosystems, and gives us hope that critically endangered species can still make a comeback.'
